Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?

TheMotleyFool

0 0

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?: https://g.foolcdn.com/editorial/images/757950/growth-trend.jpg

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been the two best-performing large-cap pharma stocks over the past 10 years. The core reason is their strong competitive positions in type 2 diabetes and obesity care.

Lilly's leading metabolic disease therapy is tirzepatide, which is sold under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity care. Bullish analysts expect this lead metabolic therapy, combined with Lilly's follow-on offerings in the space, to hit $65 billion in annual sales by 2031.

Image source: Getty Images.

Source Fool.com

Like: 0

LLY

Share